Life doesn't arrive in neat chapters. It flows, one conversation bleeding into the next, one thought quietly reshaping the one that follows. Yet our brains do something remarkable: they preserve a ...

After a century of study, physicists have theories — but they’re still not 100% sure.

Women gather at a neighborhood square in Lilongwe, Malawi, on June 8 Women gather at a neighborhood square in Lilongwe, Malawi, on June 8Zafer Goder—Anadolu/Getty Images In Malawi, one in three women ...

Exclamation marks, ellipses and ‘haha’ can’t fix our growing inability to communicate. By Nitsuh Abebe “How Many Exclamation Points Are Too Many in an Email? A Psychologist Weighs In.” A psychologist!

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

Right or (as it turns out) wrong, I wasn’t a sprinkle-your-first-name-into-conversation kind of guy. I’m not hugely self-assured, and saying the other person’s name felt forced. Or awkward. Or ...

Still, being ghosted—when the other person disappears without explanation—can be shocking, hurtful and confusing to those being left on read. According to a new psychological analysis, the impulse to ...

Dr. Grant, a contributing Opinion writer, is an organizational psychologist at the Wharton School of the University of Pennsylvania. In ancient Greek mythology, a man who falls in love with his own ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Belle Lin: Welcome to Tech News Briefing. It's Tuesday, December 23rd. I'm Belle ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...